Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Feb;25(2):353-355.
doi: 10.1007/s00520-016-3492-8. Epub 2016 Nov 24.

Response to letter to the Editors-Safety of long-term denosumab therapy

Alison T Stopeck  1 , Douglas J Warner  2
Affiliations
Comment

Response to letter to the Editors-Safety of long-term denosumab therapy

Alison T Stopeck et al. Support Care Cancer. 2017 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Alison Stopeck (MD) served as a consultant for Amgen Inc., Pfizer, Bayer, Genentech, and Clovis Pharmaceuticals. She received research funding from Amgen Inc., Novartis, Peregrine, Puma, and Bayer. Douglas Warner (MD) is an Amgen Inc. employee and has received Amgen Inc. stocks.

Comment on

References

    1. Fusco V, Bedogni A, Addeo A, Campisi G (2016) Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study? Support Care Cancer - PubMed
    1. Boissieu P, Trenque T (2016) Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab. Support Care Cancer - PubMed
    1. Stopeck A, Fizazi K, Body J, Brown J, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2015;24(1):447–455. doi: 10.1007/s00520-015-2904-5. - DOI - PMC - PubMed
    1. Stopeck A, Lipton A, Body J, Steger G, Tonkin K, Boer R, Lichinitser M, Fujiwara Y, Yardley D, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double blind study. J Clin Onc. 2010;28(35):5132–5139. doi: 10.1200/JCO.2010.29.7101. - DOI - PubMed
    1. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822. doi: 10.1016/S0140-6736(10)62344-6. - DOI - PMC - PubMed

LinkOut - more resources